This functional association together with the degree of protection from hypertension, ischemia and atherosclerosis offered by LAV-BPIFB4 treatment, could in part explain the reduced occurrence of chronic cardiovascular diseases in LLIs, endowing them also with the capacity to better recover after SARS-CoV-2 infection, too. The gene discussed is BPIFB4; the disease is ischemia.